Baxter(US:BAX) Prnewswireยท2025-11-10 13:45Core Points - The Gross Law Firm has issued a notice to shareholders of Baxter International, Inc. regarding a class action lawsuit related to the company's Novum LVP product, which allegedly has systemic defects leading to serious patient risks [1][2] - The class period for the lawsuit is from February 23, 2022, to July 30, 2025, during which Baxter is accused of making materially false and misleading statements about the safety and efficacy of the Novum LVP [1] - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs and receive updates on the case [2] Allegations Summary - Baxter's Novum LVP product reportedly suffered from defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1] - The company was allegedly aware of multiple device malfunctions and injuries but failed to take adequate remedial measures, leading to continued harm [1] - Baxter's statements regarding the product's safety, efficacy, and sales prospects were claimed to be materially false and misleading, increasing the risk of customers withdrawing the product from service [1]